Phenylketonuria clinical trials

Explore recruiting phenylketonuria clinical trials.

Recruiting phenylketonuria studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Phenylketonuria trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase 1 first-in-human study of a phenylalanine-binding polymer (phelimin) in healthy volunteers and adult, classical PKU patients

Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants with Phenylketonuria

Czechia, Italy, Spain, Netherlands, Poland, France +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3b Open-Label Study of Long-Term Neurocognitive Outcomes in Children With Phenylketonuria Treated With Sepiapterin (EPIPHENY)

Ireland, Sweden, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of SYNB1934 in Patients with PKU (SYNPHENY-3)

Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Crossover, Open-Label, Active-Controlled Study of Sepiapterin versus Sapropterin in Participants With Phenylketonuria ≥2 years of Age

Denmark, Spain, Italy, France, Germany, Slovenia +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Evaluation of AG-181 in Subjects 18 to 69 Years of Age With Phenylketonuria

Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phenylketonuria trials by city

Phenylketonuria in Toronto Phenylketonuria in Vancouver Phenylketonuria in Montreal Phenylketonuria in Calgary Phenylketonuria in Edmonton Phenylketonuria in Ottawa Phenylketonuria in Winnipeg Phenylketonuria in Quebec City Phenylketonuria in Hamilton Phenylketonuria in Kitchener Phenylketonuria in London Phenylketonuria in Halifax Phenylketonuria in New York Phenylketonuria in Los Angeles Phenylketonuria in Chicago Phenylketonuria in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease